Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
Roman M. Chabanon, Gareth Muirhead, Dragomir B. Krastev, et al.
Journal of Clinical Investigation (2018) Vol. 129, Iss. 3, pp. 1211-1228
Open Access | Times Cited: 266

Showing 51-75 of 266 citing articles:

Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING
Marine Bruand, David Barras, Marco Mina, et al.
Cell Reports (2021) Vol. 36, Iss. 3, pp. 109412-109412
Open Access | Times Cited: 89
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer
Roman M. Chabanon, Daphné Morel, Thomas Eychenne, et al.
Cancer Research (2021) Vol. 81, Iss. 11, pp. 2888-2902
Open Access | Times Cited: 85
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1–IRF1–TRIM28 Signaling Axis, Exerting Antitumor Efficacy
Jiyong Liang, Lulu Wang, Chao Wang, et al.
Cancer Immunology Research (2020) Vol. 8, Iss. 7, pp. 952-965
Open Access | Times Cited: 82
Targeting DNA repair in cancer: current state and novel approaches
Apostolos Klinakis, Dimitris Karagiannis, Θεόδωρος Ράμπιας
Cellular and Molecular Life Sciences (2019) Vol. 77, Iss. 4, pp. 677-703
Closed Access | Times Cited: 79
Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer
Zhou Li, Qiuli Xu, Litang Huang, et al.
Cancer Letters (2020) Vol. 500, pp. 163-171
Closed Access | Times Cited: 78
Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress
Wuchang Zhang, Wei Liu, Lingfei Jia, et al.
Molecular Cell (2021) Vol. 81, Iss. 10, pp. 2148-2165.e9
Open Access | Times Cited: 64
Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Alexandra Léary, David S.P. Tan, Jonathan A. Ledermann
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 58
cGAS restricts colon cancer development by protecting intestinal barrier integrity
Shuiqing Hu, Yan Fang, Xiang Chen, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 23
Open Access | Times Cited: 57
Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy
Zu Ye, Shi Yin, Susan P. Lees‐Miller, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 57
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade
Emmanuel C. Patin, Magnus T. Dillon, Pablo Nenclares, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 3, pp. e004306-e004306
Open Access | Times Cited: 52
cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy
Zi‐Jie Long, Jundan Wang, Jue‐Qiong Xu, et al.
Molecular Therapy (2022) Vol. 30, Iss. 3, pp. 1006-1017
Open Access | Times Cited: 48
Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS
Fei Wang, Mengmeng Zhao, Boran Chang, et al.
Molecular Cell (2022) Vol. 82, Iss. 11, pp. 2032-2049.e7
Open Access | Times Cited: 48
Significance of the cGAS-STING Pathway in Health and Disease
Jinglin Zhou, Zhan Zhuang, Jiamian Li, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13316-13316
Open Access | Times Cited: 36
Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
Dhanya K. Nambiar, Deepali Mishra, Rana P. Singh
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2023) Vol. 31, Iss. 4, pp. 405-421
Open Access | Times Cited: 31
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control
Kyle Concannon, Benjamin B. Morris, Carl M. Gay, et al.
Molecular Cell (2023) Vol. 83, Iss. 5, pp. 660-680
Open Access | Times Cited: 27
Agonists and Inhibitors of the cGAS-STING Pathway
Xiaoxuan Yu, Linxiang Cai, Jingyue Yao, et al.
Molecules (2024) Vol. 29, Iss. 13, pp. 3121-3121
Open Access | Times Cited: 14
Discovery of a triphenylamine-based ligand that targets mitochondrial DNA G-quadruplexes and activates the cGAS-STING immunomodulatory pathway
Xiaodong Wang, Yong-Si Liu, Mengdie Chen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116361-116361
Closed Access | Times Cited: 9
Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies
Jiawen Zhang, Sihui Yu, Qiao Peng, et al.
Cancer Biology and Medicine (2024), pp. 1-20
Open Access | Times Cited: 8
Protein arginine methyltransferases (PRMTs): Orchestrators of cancer pathogenesis, immunotherapy dynamics, and drug resistance
Yihang Gao, Chongchong Feng, Jingru Ma, et al.
Biochemical Pharmacology (2024) Vol. 221, pp. 116048-116048
Closed Access | Times Cited: 8
STING activation and overcoming the challenges associated with STING agonists using ADC (antibody-drug conjugate) and other delivery systems
Hitesh Vasiyani, Bhumika Wadhwa
Cellular Signalling (2025), pp. 111647-111647
Closed Access | Times Cited: 1
Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma.
Binghai Zhou, Lei Guo, Bo Zhang, et al.
PubMed (2019) Vol. 9, Iss. 11, pp. 2442-2455
Closed Access | Times Cited: 65
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
Elizabeth K. Lee, Ursula A. Matulonis
Cancers (2020) Vol. 12, Iss. 8, pp. 2054-2054
Open Access | Times Cited: 64
Role of Akt Activation in PARP Inhibitor Resistance in Cancer
Ferenc Gallyas, Balázs Sümegi, Csaba Szabó
Cancers (2020) Vol. 12, Iss. 3, pp. 532-532
Open Access | Times Cited: 63
Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
José Yélamos, Lucia Moreno-Lama, Jaime Jimeno, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 392-392
Open Access | Times Cited: 62
PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair
Panagiotis A. Konstantinopoulos, Stéphanie Lheureux, Kathleen N. Moore
American Society of Clinical Oncology Educational Book (2020), Iss. 40, pp. e116-e131
Open Access | Times Cited: 58

Scroll to top